Bortezomib Treatment Modulates Autophagy in Multiple Myeloma

Although the introduction of bortezomib as a therapeutic strategy has improved the overall survival of multiple myeloma (MM) patients, 15–20% of high-risk patients do not respond to bortezomib over time or become resistant to treatment. Therefore, the development of new therapeutic strategies, such...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Clin Med
Hlavní autoři: Di Lernia, Giuseppe, Leone, Patrizia, Solimando, Antonio Giovanni, Buonavoglia, Alessio, Saltarella, Ilaria, Ria, Roberto, Ditonno, Paolo, Silvestris, Nicola, Crudele, Lucilla, Vacca, Angelo, Racanelli, Vito
Médium: Artigo
Jazyk:Inglês
Vydáno: MDPI 2020
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7073518/
https://ncbi.nlm.nih.gov/pubmed/32085480
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm9020552
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky